source
- Gilead pushes further into immunology, touts inflammation drug pipelineGilead Sciences’ senior leadership has repeatedly emphasized the company’s long‑term ambition to expand beyond its virology roots into the inflammatory and autoimmune space. The messaging, delivere…
- Kyverna reports positive one-year CAR-T results for rare stiff person syndrome, supporting FDA filingKyverna Therapeutics announced that its CAR-T therapy for stiff person syndrome showed positive results after one year of treatment. The trial involved patients with the rare autoimmune disorder,…